L 2-401
L 2-401 Basic information
- Product Name:
- L 2-401
- Synonyms:
-
- 4-[(4-Fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione
- CCG 50014
- L 2-401
- 1,2,4-Thiadiazolidine-3,5-dione, 4-[(4-fluorophenyl)methyl]-2-(4-methylphenyl)-
- 4-(4-Fluorobenzyl)-2-p-tolyl-1,2,4-thiadiazolidine-3,5-dione
- CCG50014;CCG 50014
- CS-563
- CCG-50014 >=98% (HPLC)
- CAS:
- 883050-24-6
- MF:
- C16H13FN2O2S
- MW:
- 316.35
- EINECS:
- 604-604-1
- Product Categories:
-
- Inhibitors
- Mol File:
- 883050-24-6.mol
L 2-401 Chemical Properties
- Density
- 1.398±0.06 g/cm3 (20 ºC 760 Torr)
- storage temp.
- 2-8°C
- solubility
- DMSO: soluble5mg/mL, clear (warmed)
- form
- powder
- color
- white to beige
- InChI
- 1S/C16H13FN2O2S/c1-11-2-8-14(9-3-11)19-15(20)18(16(21)22-19)10-12-4-6-13(17)7-5-12/h2-9H,10H2,1H3
- InChIKey
- QUIIIYITNGOFEI-UHFFFAOYSA-N
- SMILES
- Fc1ccc(cc1)C[n]2[c]([s][n]([c]2=O)c3ccc(cc3)C)=O
L 2-401 Usage And Synthesis
Description
CCG-50014 is an inhibitor of regulator of G protein signaling 4 (RGS4) (IC50 = 30 nM) and is > 20-fold selective for RGS4 over other RGS proteins. RGS proteins bind to the Gα subunits of activated heterotrimeric G proteins and accelerate the rate of GTP hydrolysis, acting as GTPase-activating proteins. CCG-50014 irreversibly binds and destabilizes RGS4 with no effect on Gα0, while blocking GTPase activity and Gα0-dependent translocation of RGS4 to the membrane.
Uses
CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site[1]. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test[2].
in vivo
CCG50014 (10, 30, or 100 nM) attenuates the nociceptive responses during the late phase in a dose-dependent manner[2].
IC 50
RGS4: 30 nM (IC50); RGS8: 11 μM (IC50); RGS16: 3.5 μM (IC50); RGS19: 0.12 μM (IC50)
References
[1] Blazer LL, et al. A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins. Biochemistry. 2011 Apr 19;50(15):3181-92. DOI:10.1021/bi1019622
[2] Yoon SY, et al. Intrathecal RGS4 inhibitor, CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test. Anesth Analg. 2015 Mar;120(3):671-7. DOI:10.1213/ANE.0000000000000607
L 2-401Supplier
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Tel
- 025-846993838003-8003 18013301590
- njduly@126.com
- Tel
- 400-400-164-7117 18317119277
- product02@bidepharm.com
- Tel
- 021-52996696,15000506266 15000506266
- Tel
- 888-539-0666
- info@emmx.com